Back to Results

Genenta Science SpA ADR (GNTA)

Genenta Science S.p.A. ADR (NASDAQ: GNTA) is a depositary receipt representing common stock of Genenta Science S.p.A., a clinical-stage biotechnology company based in Milan, Italy. The company is focused on developing hematopoietic stem cell gene therapies for solid tumors. Its lead candidate, Temferon, is in Phase 1/2a clinical testing for glioblastoma multiforme in patients with an unmethylated MGMT gene promoter. Genenta is also studying Temferon in additional solid tumor settings, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Beyond this program, the company is working on a biologic platform designed to deliver immunomodulatory molecules directly to tumors through infiltrating monocytes and macrophages. Genenta was incorporated in 2014.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-GNTA
$1.19
70.3% Upside
Bargain
$6.84
875.6% Upside
Bargain
Fair
0.0%
0.7x
16.75 M
-7.759 M
33.3%
58.8%
3.5
105.3%
Valuation • Fair Value

Genenta Science SpA ADR (NASDAQ-GNTA) Fair Value by Valuation Model

Review the available estimates for Genenta Science SpA ADR (NASDAQ-GNTA), including Comps Fair Value.

Primary Valuation Read

Fair Value

$1.19

Estimated upside of 70.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$1.19

Comparable-company valuation reference.

Analyst Price Target

$6.84

Analysts imply upside of 875.6%.

How to read these valuation models

Use the 4 available valuation references for Genenta Science SpA ADR (NASDAQ-GNTA) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Genenta Science SpA ADR (NASDAQ-GNTA)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-7.725 M

Current operating profitability reference.

EBITDA Forecast

-43.763 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Genenta Science SpA ADR (NASDAQ-GNTA) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Genenta Science SpA ADR (NASDAQ-GNTA)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

3

Weak quality score that deserves closer review.

Altman Z-Score

3.5

Relatively strong balance-sheet zone.

FCF / Net Income

105.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Genenta Science SpA ADR (NASDAQ-GNTA). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Genenta Science SpA ADR (NASDAQ-GNTA)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Genenta Science SpA ADR (NASDAQ-GNTA). No upcoming dividend amount or event date is currently available.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Genenta Science SpA ADR (NASDAQ-GNTA) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Genenta Science SpA ADR (NASDAQ-GNTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Genenta Science SpA ADR (NASDAQ-GNTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Genenta Science SpA ADR (NASDAQ-GNTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Genenta Science SpA ADR (NASDAQ-GNTA) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Genenta Science SpA ADR (NASDAQ-GNTA) Stock FAQ

Data-supported answers about Genenta Science SpA ADR (NASDAQ-GNTA), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.19
Estimated upside 70.3%
Valuation Rating
Undervalued
Estimated upside of 70.3%
Analyst Target
$6.84
Implied upside 875.6%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Genenta Science SpA ADR (NASDAQ-GNTA) is $1.19. This implies an estimated upside of 70.3% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 70.3% versus the current market price.

The available analyst price target for Genenta Science SpA ADR (NASDAQ-GNTA) is $6.84. The analyst target implies estimated upside of 875.6%.

The current financial health read for Genenta Science SpA ADR (NASDAQ-GNTA) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Genenta Science SpA ADR (NASDAQ-GNTA).

The current market capitalization listed for Genenta Science SpA ADR is 16.75 M.

The current enterprise value listed for Genenta Science SpA ADR is -7.759 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Genenta Science SpA ADR is NASDAQ-GNTA, and the stock is listed on NASDAQ.

Genenta Science SpA ADR (NASDAQ-GNTA) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Genenta Science SpA ADR is 33.3%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Genenta Science SpA ADR is 58.8%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B